Report Category

Pharmaceutical Market Research Reports

In-depth market intelligence covering drug development, CDMO outsourcing, API manufacturing, biosimilars, oncology, cell & gene therapy, clinical trials, and specialty pharma — with 10-year forecasts, 15–25 KOL interviews per report, and competitive landscape analysis.

340+
Reports
10yr
Forecasts
15–25
KOL Interviews

Pharmaceutical Industry Market Intelligence

The global pharmaceutical market continues to evolve rapidly, driven by the acceleration of biologics and biosimilar development, the expansion of CDMO outsourcing models, advances in cell and gene therapy manufacturing, and the growing demand for complex drug delivery systems. InsightAce Analytic's pharmaceutical report library covers the full value chain — from active pharmaceutical ingredient sourcing and continuous manufacturing to clinical trial logistics and post-market commercialization.

CDMO & Contract ManufacturingOutsourcing models, capacity analysis, competitive positioning
API & Drug SubstanceSupply chain, HPAPI, peptide APIs, oligonucleotides
Oncology & Immuno-OncologyADCs, bispecifics, CAR-T, radiopharmaceuticals
Drug Delivery SystemsLNP platforms, nasal, transdermal, implantable devices
Biosimilars & BiologicsPatent cliffs, pipeline analysis, market penetration
Cell & Gene TherapyManufacturing, logistics, vein-to-vein supply chain
Clinical Trials & CRODecentralized trials, site management, real-world evidence
Rare Diseases & Orphan DrugsRegulatory pathways, pricing, competitive dynamics
CNS & NeurologyNeurodegeneration, psychiatric, digital therapeutics

Rituximab Biosimilar Market Size, Share & Trends Analysis Report By Brand, By Application, By Route of Administration, By Molecule Type, By Distribution Channel Region And Segment Forecasts, 2025-2034

Rituximab Biosimilar Market is expected to grow at a 12.3% CAGR during the forecast period for 2025-2034. Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the standard and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, as well as an autoimmune disorder such as Rheumatoid arthritis. Rituximab i...

ID: 1081 180 Pages June 2025

Synthetic Lethality-based Drugs and Targets Market Size, Share & Trends Analysis Report By Type (Monotherapy, Combination Therapy), By Application (Medical Research Institution, Hospital and Clinic), By Region, And By Segment Forecasts, 2025-2034

Synthetic Lethality-based Drugs and Targets Market Size is predicted to witness a 14.5% CAGR during the forecast period for 2025-2034.  Synthetic lethality refers to a genetic and cancer treatment notion in which the simultaneous dysfunction of two genes results in cell death, whereas the dysfunction of either gene alone does not have the same effect. This method is employed to create precise cancer treatments that take advantage of parti...

ID: 2657 180 Pages June 2025

Vitamins, Minerals and Supplements CDMO Market Size, Share & Trends Analysis Distribution by Types (Vitamins, Minerals, Dietary Supplements), Dosage Form (Tablets & Capsules, Powder, Softgel), Service Type (Product Formulation and Development, Manufacturing and Packaging, Research & Development (R&D), Regulatory Compliance), Company Size- and Segment Forecasts, 2025-2034

Vitamins, Minerals and Supplements CDMO Market Size is valued at USD 41.74 Bn in 2024 and is predicted to reach USD 97.60 Bn by the year 2034 at an 9.0% CAGR during the forecast period for 2025-2034. The Vitamins, Minerals, and Supplements (VMS) Contract Development and Manufacturing Organization (CDMO) market is a rapidly growing segment within the broader nutraceutical industry. VMS CDMOs provide comprehensive services for the development, m...

ID: 2669 180 Pages June 2025

Lentiviral Vector (LVV) CDMO Services Market Size, Share & Trends Analysis Report By Service Type (Process Development & Analytical Services, GMP Manufacturing of LVV, Non-GMP / Preclinical LVV Production, Fill–Finish & Packaging Services, Quality, Regulatory & Tech Transfer Services, Integrated End-to-End LVV CDMO Services), By Scale / Manufacturing Stage (Preclinical / Research-Scale Manufacturing, Early Clinical Manufacturing (Phase I / II), Late-Clinical & Commercial-Scale Manufacturing (Phase III / Commercial)), By Application, By End User, By Region, and By Segments Forecast, 2025-2034

Global Lentiviral Vector (LVV) CDMO Services Market Size is predicted to record a 9.0% CAGR during the forecast period for 2025-2034. Lentiviral vectors (LVs) CDMO Services are helpful for gene transfer in mammalian cells because they can efficiently transmit genes from one cell type to another. Lentivirus infections can incubate for a long time and persist for years in animals and humans. The onset of symptoms and initial infection could happen...

ID: 2374 180 Pages June 2025

Next Generation Drug Conjugates Market Size, Share & Trends Analysis Report, By Type (Peptide Receptor Radionuclide Therapy, Ligand mediated RNAi Conjugate, Ligand Conjugated Anti Sense Medicine and Peptide Drug Conjugate), By Type of Targeting Ligand (Amino Sugar, Peptide, Lipid, Small Molecule and Virus-like Particles), By Type of Payload (Peptide, Small Molecule, Oligonucleotide, Radionuclide), By Type of Therapy (Monotherapy, Combination Therapy), By Route of Administration, By Target Indications, By Region, Forecasts, 2025-2034

Global Next Generation Drug Conjugates Market Size was valued at USD 2.9 Bn in 2024 and is predicted to reach USD 12.1 Bn by 2034 at a 15.2% CAGR during the forecast period for 2025-2034. The next-generation drug conjugates (NGDCs) market represents a paradigm shift in cancer therapy, leveraging the synergistic potential of targeted drug delivery and enhanced therapeutic efficacy. NGDCs are a class of bioconjugates that combine cytotoxic payload...

ID: 2482 180 Pages June 2025

Lipid Nanoparticle Raw Materials Market Size, Share & Trends Analysis Report, By Application (Therapeutics and Research), By Product (Kits, Reagents, Others), By Disease Indication (Cancer, Infectious Diseases, Blood Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Region, Forecasts, 2025-2034

Global Lipid Nanoparticle Raw Materials Market Size was valued at USD 239.4 Mn in 2024 and is predicted to reach USD 421.2 Mn by the year 2034 at a 6.0% CAGR during the forecast period for 2025-2034. Lipids, stabilizers, and occasionally targeting ligands make up the different raw elements that make up lipid nanoparticles. Phospholipids, such as phosphatidylcholine and cholesterol, are often utilized lipids. Several important reasons are dr...

ID: 2367 180 Pages June 2025

IVD Contract Manufacturing Market Size, Share & Trends Analysis Report By Type of Nanoparticle Formulated (Organic, Inorganic, and Carbon-based Nanoparticles), By Organic Nanoparticle Formulated, By Inorganic Nanoparticle Formulated, By Scale of Operation, Region, And Segment Forecasts, 2025-2034

IVD Contract Manufacturing Market Size is valued at 15.88 billion in 2024 and is predicted to reach 50.50 billion by the year 2034 at a 12.4% CAGR during the forecast period for 2025-2034. Key Industry Insights & Findings from the Report: The growing occurence of infectious diseases and the need for early diagnosis drive the demand for IVD devices, which in turn drives the growth of the IVD contract manufacturing market. Increasing reg...

ID: 1882 180 Pages June 2025

Super Generics Market Size, Share & Trends Analysis Report By Therapeutic Area (Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), By Route of Administration (Intravenous, Oral, Subcutaneous and Others), By Type of Molecule (Small and Other Molecules), By Type of Small Molecule (Generics and Other Small Molecules), By Type of Product (Aerosols, Capsules, Prefilled Syringes, Tablets, Vials and Other Products), By Region, And By Segment Forecasts, 2025-2034

Global Super Generics Market Size is valued at USD 77.4 Bn in 2024 and is predicted to reach USD 157.7 Bn by the year 2034 at a 7.5% CAGR during the forecast period for 2025-2034. Super generics, commonly referred to as value-added generics, are improved versions of generic medications. They provide extra benefits above regular generics, such as better efficacy, safety, and convenience of use. Super generics are created using unique formulation ...

ID: 2437 180 Pages June 2025

Radioactive Tracer Market Size, Share & Trends Analysis Report By Tracer Type , Test Type (PET, SPECT, Others), Application (Oncology, Pulmonary, Neurology, Cardiology, Others), End User, Region And Segment Forecasts, 2025-2034

Global Radioactive Tracer Market Size is valued at USD 3.5 billion in 2024 and is predicted to reach USD 7.19 billion by the year 2034 at a 7.4% CAGR during the forecast period for 2025-2034.   The radioactive tracer is a chemical molecule in which one or more atoms have been replaced with a radionuclide. Radioactive tracers are utilized in imaging studies to assist in diagnosing internal health issues. These tracers emit particles that m...

ID: 2042 180 Pages June 2025

Biostatistics Consulting Service Market Size, Share & Trends Analysis Report By Application (Pharmaceutical Company, Medical Device Company, and Others), By Type (Project Management and Data Management), By Region, And By Segment Forecasts, 2025-2034

Global Biostatistics Consulting Service Market Size is predicted to witness a 10.0% CAGR during the forecast period for 2025-2034. Biostatistics is the applied field of statistics for biological, life science, and health-related data. It is utilized by consultants specialising in statistical tools, analysis, study design, data interpretation, medical research, clinical trials, and epidemiological investigations. The rising existance of chronic d...

ID: 2318 180 Pages June 2025

Key Pharmaceutical Sub-Segments We Cover

CDMO & Contract Manufacturing

The pharmaceutical CDMO market is expanding rapidly as drug developers increasingly outsource manufacturing to reduce capital expenditure and accelerate time-to-market. Our CDMO reports cover small molecule contract manufacturing, biologics CDMO, fill-finish services, and continuous manufacturing outsourcing with competitive landscape analysis of leading CDMOs worldwide.

API & Drug Substance Manufacturing

Active pharmaceutical ingredient sourcing and manufacturing is a critical strategic decision for pharma companies. Our API reports analyze supply chain dynamics, pricing trends, geographic manufacturing shifts, and the growing demand for high-potency APIs, peptide APIs, and oligonucleotide synthesis.

Drug Delivery Systems

Innovation in drug delivery — from nasal and transdermal systems to lipid nanoparticle platforms and controlled-release formulations — is reshaping how therapeutics reach patients. We cover the full spectrum of delivery technologies including inhalation devices, implantable systems, and targeted nanoparticle carriers.

Oncology & Immuno-Oncology

Oncology remains the largest therapeutic area by R&D investment. Our reports cover bispecific antibodies, antibody-drug conjugates, checkpoint inhibitors, CAR-T therapies, radiopharmaceuticals, and companion diagnostics with pipeline analysis and competitive positioning.

Biosimilars & Biologics

The biosimilar market is driven by patent cliffs of blockbuster biologics and increasing regulatory clarity. We analyze biosimilar development pipelines, interchangeability trends, market penetration dynamics, and the competitive strategies of both originator and biosimilar manufacturers.

Why Choose InsightAce for Pharmaceutical Market Intelligence?

  • Original primary research — 15–25 KOL interviews per report with pharma executives, CDMO leaders, formulators, and regulatory experts
  • 10-year market forecasts — analyst-built models with top-down and bottom-up triangulation, covering 2026–2035
  • Competitive landscape — detailed profiling of 15–25 companies per report including revenue analysis, pipeline mapping, and strategic positioning
  • Segmentation depth — by type, application, technology, formulation, route of administration, end-user, and region
  • Post-purchase support — dedicated analyst hours for follow-up questions, custom data tables, and presentation-ready slides

Frequently Asked Questions

How many pharmaceutical market research reports does InsightAce publish?

InsightAce Analytic has published 340+ pharmaceutical market research reports covering drug development, CDMO outsourcing, API manufacturing, biosimilars, clinical trials, and specialty pharma with 10-year forecasts.

What pharmaceutical sub-segments does InsightAce cover?

We cover CDMO & contract manufacturing, API & drug substance, drug delivery systems, oncology & immuno-oncology, biosimilars & biologics, cell & gene therapy, rare diseases & orphan drugs, CNS & neurology, and clinical trials & CRO markets.

What is included in InsightAce pharmaceutical reports?

Each report includes 10-year market size forecasts, competitive landscape with 15-25 company profiles, segmentation by type, application, and region, 15-25 KOL interviews, and post-purchase analyst support.

Can I customize a pharmaceutical report?

Yes. Every report purchase includes free 10% customization. You can add countries, extend the forecast period, add company profiles, or request specific segmentation cuts.

How do I request a sample pharmaceutical report?

Click "Request Sample" on any report card to receive an executive summary, table of contents, and sample data tables delivered to your email.